Global Anticoagulant Reversal Drugs Market Size By Product Type(Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, Idarucizumab, Protamine, and Others), By Distribution Channel(Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), By Geographic Scope And Forecast

Anticoagulant Reversal Drugs Market Size And Forecast

Anticoagulant Reversal Drugs Market size was valued at USD 1250.4 Million in 2021 and is projected to reach USD 3,652.8 Million by 2030, growing at a CAGR of 12.65% from 2022 to 2030.

The rising number of bleeding disorders, the introduction of new drugs, and the growing number of cases requiring anticoagulant therapies are some of the factors anticipated to foster market growth during the forecast period. The Global Anticoagulant Reversal Drugs Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Anticoagulant Reversal Drugs Market Definition

Anticoagulant drugs are also termed as blood thinning agent is a pharmaceuticals drugs that helps in reducing or preventing the blood coagulation and are commonly used in the treatment of thrombolism. Anticoagulant reversal drugs such as Idarucizumab reverse the anticoagulant effects given in condition where bleeding complication occurs or overdose of anticoagulant therapy. Anticoagulant reversal drugs are required to reverse the effect of anticoagulation in certain situations such as unplanned surgery, overdose of anticoagulant therapy, and uncontrolled bleeding. Anticoagulant reversal drugs are used in medical conditions such as venous thromboembolism, atrial fibrillation (AF), mechanical valve replacement, and other coagulation disorders such as antiphospholipid antibody syndrome and Factor V Leiden. Oral anticoagulants are widely used and are highly effective in preventing thromboembolism among AFib patients. However, the use of anticoagulants may lead to bleeding in AFib patients; thus, anticoagulant reversal drugs are used to prevent bleeding.

Global Anticoagulant Reversal Drugs Market Overview

Approval and launch of new therapies, increasing prevalence of bleeding disorders, and rise in the incidence of indications for anticoagulant therapy are some of the major factors driving the market. Approval and launch of new reversal agents for anticoagulants are significantly driving the market. For instance, in May 2018, the U.S. FDA approved Andexxa by Portola Pharmaceuticals as the first factor Xa inhibitor antidote. When an anticoagulation reversal drug is required due to uncontrolled or life-threatening bleeding, this reversal agent is indicated for patients treated with apixaban (Eliquis) and rivaroxaban (Xarelto). The expected launch of Andexxa under an Early Supply Program with Generation 1 product was in early June. However, the company announced the first sale of Ondexxya in Europe in August 2019 due to a larger number of patients taking Factor Xa inhibitor in the region as compared to the U.S. Andexxa received both FDA breakthrough therapy and U.S. orphan drug designations.

In addition, the growing burden of cardiovascular diseases globally is expected to be a major factor for the increasing demand of anticoagilant reversal drugs, which in turn surges the market growth in the coming years. According to the “Global Health And Wellness Report”, about 40% of the adult population in the United States have been diagnosed with a cardiovascular condition in 2018. Similarly, there were around 7.4 million people living with heart and circulatory diseases in the United Kingdom and more than 43,000 people under the age of 75 in the United Kingdom die from heart and circulatory diseases each year as per the British Heart Foundation Centre, 2018 report. Moreover, as per the estimates of the Heart Disease and Stroke Statistics 2019, the lifetime risk of atrial fibrillation recently has been estimated to be approximately 1 in 3 among whites in the United States.

However, the high cost of these reversal therapies is anticipated to restrain the market growth. As per the American College of Cardiology, 4-F PCC (Kcentra) helps in treating bleeding cases caused by rivaroxaban and apixaban and it is dosed at 50 units/kg. Its average wholesale price is USD 2.90 per unit, therefore treating a patient whose weight is 100 kg would cost around USD 14,500.

Global Anticoagulant Reversal Drugs MarketSegmentation Analysis

The Global Anticoagulant Reversal Drugs Market is segmented based on Product Type, Distribution Channel, and Geography.

Anticoagulant Reversal Drugs Market by Product Type

• Prothrombin Complex Concentrates• Phytonadione• Andexanet Alfa• Idarucizumab• Protamine• Others

Based on Product Type, the market is bifurcated into Prothrombin Complex Concentrates, Phytonadione, Andexanet Alfa, Idarucizumab, Protamine, and Others. The idarucizumab segment accounted for the largest share of 36.77% and is anticipated to maintain its lead over the forecast period. This is attributed to the high revenue generation by idarucizumab in major geographies. Based on product type, the market is segmented into prothrombin complex concentrates, phytonadione (vitamin k), andexanet alfa, idarucizumab, protamine, and others.

 Anticoagulant Reversal Drugs Market by Distribution Channel

• Hospital Pharmacy• Retail Pharmacy• Online Pharmacy

Based on Distribution Channel, the market is bifurcated into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. Hospital pharmacy dominated the market with a 49.2% share in 2019. This is attributed to the fact that hospitals are the primary centers for the diagnosis and treatment of different types of bleeding disorders. Uncontrolled bleeding during emergency conditions is further driving the segment. On the basis of the distribution channel, the market is classified into retail pharmacy, hospital pharmacy, and online pharmacy.

Anticoagulant Reversal Drugs Market by Geography

• North America• Europe• Asia Pacific• Rest of the world

On the basis of Geography, the Global Anticoagulant Reversal Drugs Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America held the largest revenue share of 39.62% in 2019 and is expected to maintain the lead throughout the forecast period. The U.S. accounted for the leading share in the North American market. Key factors contributing to its growth include high healthcare expenditure and favorable healthcare reimbursement policies for costly drugs. In addition, the easy availability of these reversal drugs during emergency conditions is driving the regional market.

Key Players

The “Global Anticoagulant Reversal Drugs Market” study report will provide a valuable insight with an emphasis on the global market. The major players in the market are Portola Pharmaceuticals; Boehringer Ingelheim; CSL Behring; Bausch Health Companies Inc.; Octapharma AG; Dr. Reddy’s Laboratories; AMAG Pharmaceuticals, Inc.; Pfizer, Inc.; SGPharma Pvt. Ltd.; and Alps Pharmaceutical Ind. Co., Ltd.

The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• April, 2018 – The US Food and Drug Administration (FDA) has given full approval to Boehringer Ingelheim’s Praxbind (idarucizumab), a particular reversal medication for Pradaxa (dabigatran etexilate mesylate). When reversing the anticoagulant effects of dabigatran is required for emergency surgery/urgent operations or in life-threatening or uncontrolled bleeding, Praxbind is prescribed for patients taking Pradaxa.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post sales analyst support

Customization of the Report

In case of any please connect with our sales team, who will ensure that your requirements are met.